PUBLISHER: Polaris Market Research | PRODUCT CODE: 1719922
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1719922
The global transcatheter aortic valve replacement market size is expected to reach USD 12.91 billion by 2034, according to a new study by Polaris Market Research. The report "Transcatheter Aortic Valve Replacement (TAVR) Market Size, Share, Trends, Industry Analysis Report: By Mechanism (Self-Expandable and Balloon-Expandable), Material, Procedure, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Transcatheter aortic valve replacement (TAVR), also known as transcatheter aortic valve implantation, is a less invasive process of replacing a damaged or failing aortic valve with an artificial valve. The procedure involves a doctor inserting a catheter into a blood vessel in the leg and guiding it to the heart. A replacement valve is then inserted through the catheter and deployed to push the old valve out of the way. TAVR has several advantages over open-heart surgery, including lower discomfort, less blood loss, and reduced infection risks. Patients undergoing TAVR can usually walk the same day as their procedure and go home the next day.
The rising prevalence of aortic valve stenosis (AS) and rising preference for minimally invasive procedures are a few of the key factors driving the transcatheter aortic valve replacement market growth. The growing worldwide geriatric population is also contributing to the market expansion. Older adults are more vulnerable to cardiovascular diseases, particularly aortic valve stenosis, necessitating effective treatments such as TAVR.
The increasing prevalence of cardiovascular disorders, such as coronary artery disease and heart failure, contributes to the demand for TAVR, thereby driving the market demand. In addition, technological advancements in TAVR technology are fueling the development of the market. Advances in catheter technology, imaging methods, and valve design have helped improve the accessibility, safety, and effectiveness of TAVR procedures.
Key Highlights of Transcatheter Aortic Valve Replacement Market Report
Based on end use, the hospitals segment led the market with an 89.4% revenue share of the global market in 2024. The segment's growth is driven by the rising prevalence of aortic stenosis, an increase in TAVR treatments, and the presence of favorable reimbursement policies in both developed and developing countries.
Based on mechanism, the balloon-expandable segment held the largest TAVR market share of 57.4% in 2024. The non-repositionable, intra-annular architecture and decreased stent frame profile of balloon-expandable TAVR allow for easy coronary access.
North America led the global market with a 40% revenue share in 2024, driven by the presence of an advanced healthcare system and rising rates of disorders such as aortic stenosis (AS) and aortic regurgitation in the region.
The Europe transcatheter aortic valve replacement market is predicted to register the fastest growth during the forecast period. Several factors, including economic progress, regulatory implications, and new product introductions in the EU drive the regional market expansion.
Boston Scientific Corporation; Direct Flow Medical, Inc.; Edwards Lifesciences Corporation; HLT, Inc.; Abbott Laboratories; JenaValve Technology, Inc.; Medtronic plc; Meril Life Sciences Pvt. Ltd.; St. Jude Medical, Inc.; Medtronic; and Transcatheter Technologies GmbH are a few of the key players in the market.
Polaris Market Research has segmented the global transcatheter aortic valve replacement market report on the basis of mechanism, material, procedure, end use, and region:
Transcatheter Aortic Valve Replacement Market Segmentation